Stryker Corporation
Stryker Reports Strong 2025 Results and Positive 2026 Outlook
Summary
Stryker Corporation announced its fourth quarter and full-year 2025 operating results, showing net sales increased by 11.4% to $7.2 billion in the quarter and 11.2% to $25.1 billion for the full year. Reported EPS increased by 56.0% to $2.20 for the quarter and 8.2% to $8.40 for the full year. The company also provided an outlook for 2026, expecting organic net sales growth of 8.0% to 9.5% and adjusted net earnings per diluted share of $14.90 to $15.10. Stryker's performance was driven by strong demand across its MedSurg, Neurotechnology, and Orthopaedics segments.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement